Comera Investor Presentation Deck

Comera Life Sciences Investment Highlights Near-Term Milestones Lower-Risk Development Multiple Shots on Goal Capital Efficient • Focus on reformulation of existing drugs ● ● Comera LIFE SCIENCES Partnerships yield near-term licensing fees; IND filing milestones within ~2 years SQore™ technology can be applied across multiple partnership and pipeline programs Business model characterized by low operating cost and development spend

View entire presentation